Plain-English translation of NCT07600476 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is one of the first times this treatment has been tested in people.
This is a first-in-human trial of , a new medication designed to activate the immune system to fight advanced skin cancers including melanoma and squamous cell carcinoma. The trial's main goal is to find the safest and most effective dose of this medication and to see how your body processes it. Researchers will also gather early information about whether the medication actually works against these cancers.
Current treatments don't work well enough for all patients with advanced skin cancers, and some people have no good options left. This medication is designed to work in a new way — by stimulating the immune system — so researchers want to test whether it could become a new treatment option for these patients.
You likely qualify if…
You likely don't qualify if…
You would receive increasing doses of , starting at a low dose and moving to higher doses as safety is confirmed. The trial will involve multiple visits where researchers check your health, run blood tests, and monitor how the medication affects your body and cancer. The exact schedule and duration aren't detailed in this summary, so you'd learn the specifics during screening — but like most early-stage trials, you should expect regular check-ins over several months.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
Germany